Myeloma propagating cells, drug resistance and relapse

Stem Cells

Volumn 33, Issue 11, 2015, Pages 3205-3211

  Karadimitris, Anastasios ^a,b   Chaidos, Aristeidis ^a,b   Caputo, Valentina ^a   Goudevenou, Katerina ^a   Ponnusamy, Kanagaraju ^a   Xiao, Xiaolin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

B lymphocytes; Cancer; Cancer stem cells; Epigenetics; Flow cytometry; Hematologic malignancies; Stem cell plasticity; Xenotransplantation

Indexed keywords

ARTICLE; B LYMPHOCYTE; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CELL LINEAGE; CONCEPTUAL FRAMEWORK; GENOMICS; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE MYELOMA PROPAGATING ACTIVITY; MULTIPLE MYELOMA PROPAGATING CELL; MYELOMA CELL; NONHUMAN; OVERALL SURVIVAL; ANIMAL; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; PHYSIOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84944566658     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2199     Document Type: Article

References (77)

1. Anderson KC, Carrasco RD., Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
2. Rollig C, Knop S, Bornhauser M., Multiple myeloma. Lancet 2015; 385: 2197-2208.
3. Bianchi G, Munshi NC., Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015; 125: 3049-3058.
4. Fowler JA, Edwards CM, Croucher PI., Tumor-host cell interactions in the bone disease of myeloma. Bone 2011; 48: 121-128.
5. Terpos E, Sezer O, Croucher P, et al., Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098-1104.
6. Valent P, Bonnet D, De Maria R, et al., Cancer stem cell definitions and terminology: The devil is in the details. Nat Rev Cancer 2012; 12: 767-775.
7. Saltarella I, Lamanuzzi A, Reale A, et al., Identify multiple myeloma stem cells: Utopia? World J Stem Cells 2015; 7: 84-95.
8. Kellner J, Liu B, Kang Y, et al., Fact or fiction-identifying the elusive multiple myeloma stem cell. J Hematol Oncol 2013; 6: 91.
9. Abe M, Harada T, Matsumoto T., Concise review: Defining and targeting myeloma stem cell-like cells. Stem Cells 2014; 32: 1067-1073.
10. Hosen N., Multiple myeloma-initiating cells. Int J Hematol 2013; 97: 306-312.
11. Hajek R, Okubote SA, Svachova H., Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 2013; 163: 551-564.
12. Kyle RA, Therneau TM, Rajkumar SV, et al., Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
13. Kuehl WM, Bergsagel PL., Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Investig 2012; 122: 3456-3463.
14. Morgan GJ, Walker BA, Davies FE., The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
15. Chapman MA, Lawrence MS, Keats JJ, et al., Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
16. Walker BA, Wardell CP, Melchor L, et al., Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012; 120: 1077-1086.
17. Egan JB, Shi CX, Tembe W, et al., Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
18. Keats JJ, Chesi M, Egan JB, et al., Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-1076.
19. Bolli N, Avet-Loiseau H, Wedge DC, et al., Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5: 2997.
20. Lohr JG, Stojanov P, Carter SL, et al., Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
21. Lawrence MS, Stojanov P, Mermel CH, et al., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
22. Greaves M, Maley CC., Clonal evolution in cancer. Nature 2012; 481: 306-313.
23. Melchor L, Brioli A, Wardell CP, et al., Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014; 28: 1705-1715.
24. Walker BA, Wardell CP, Melchor L, et al., Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390.
25. Oracki SA, Walker JA, Hibbs ML, et al., Plasma cell development and survival. Immunol Rev 2010; 237: 140-159.
26. Allman D, Pillai S., Peripheral B cell subsets. Curr Opin Immunol 2008; 20: 149-157.
27. Pieper K, Grimbacher B, Eibel H., B-cell biology and development. J Allergy Clin Immunol 2013; 131: 959-971.
28. McHeyzer-Williams LJ, McHeyzer-Williams MG., Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
29. Nutt SL, Taubenheim N, Hasbold J, et al., The genetic network controlling plasma cell differentiation. Semin Immunol 2011; 23: 341-349.
30. Hetz C., The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol 2012; 13: 89-102.
31. Auner HW, Cenci S., Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. Br J Haematol 2015; 168: 14-25.
32. Rawstron AC, Orfao A, Beksac M, et al., Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438.
33. Mei HE, Wirries I, Frolich D, et al., A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 2015; 125: 1739-1748.
34. Mellstedt H, Hammarstrom S, Holm G., Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 1974; 17: 371-384.
35. Warner TF, Krueger RG., Circulating lymphocytes and the spread of myeloma. Review of the evidence. Lancet 1978; 1: 1174-1176.
36. Kreso A, Dick JE., Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275-291.
37. Pilarski LM, Belch AR., Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198-3204.
38. Szczepek AJ, Bergsagel PL, Axelsson L, et al., CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood 1997; 89: 1824-1833.
39. Szczepek AJ, Seeberger K, Wizniak J, et al., A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844-2855.
40. Rasmussen T, Jensen L, Johnsen HE., Levels of circulating CD19+ cells in patients with multiple myeloma. Blood 2000; 95: 4020-4021.
41. Rasmussen T, Jensen L, Johnsen HE., The CD19 compartment in myeloma includes a population of clonal cells persistent after high-dose treatment. Leukemia Lymphoma 2002; 43: 1075-1077.
42. Rasmussen T, Lodahl M, Hancke S, et al., In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leukemia Lymphoma 2004; 45: 1413-1417.
43. Chaidos A, Barnes CP, Cowan G, et al., Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2013; 121: 318-328.
44. Reid S, Yang S, Brown R, et al., Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 2010; 32: e190-196.
45. Chiron D, Surget S, Maiga S, et al., The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol 2012; 156: 679-683.
46. Christensen JH, Jensen PV, Kristensen IB, et al., Characterization of potential CD138 negative myeloma "stem cells". Haematologica 2012; 97: e18-20.
47. Caraux A, Klein B, Paiva B, et al., Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal C. Haematologica 2010; 95: 1016-1020.
48. Yaccoby S, Epstein J., The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576-3582.
49. Epstein J, Yaccoby S., The SCID-hu myeloma model. Methods Mol Med 2005; 113: 183-190.
50. Hosen N, Matsuoka Y, Kishida S, et al., CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia 2012; 26: 2135-2141.
51. Kim D, Park CY, Medeiros BC, et al., CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 2012; 26: 2530-2537.
52. Yata K, Yaccoby S., The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004; 18: 1891-1897.
53. Drewinko B, Alexanian R, Boyer H, et al., The growth fraction of human myeloma cells. Blood 1981; 57: 333-338.
54. Matsui W, Wang Q, Barber JP, et al., Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
55. Peacock CD, Wang Q, Gesell GS, et al., Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 4048-4053.
56. Matsui W, Huff CA, Wang Q, et al., Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
57. Pilarski LM, Seeberger K, Coupland RW, et al., Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol 2002; 30: 221-228.
58. Danner R, Chaudhari SN, Rosenberger J, et al., Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PLoS One 2011; 6: e19826.
59. Chiron D, Maiga S, Surget S, et al., Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J 2013; 3: e120.
60. Knutson SK, Wigle TJ, Warholic NM, et al., A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-896.
61. Chaidos A, Caputo V, Gouvedenou K, et al., Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2014; 123: 697-705.
62. Rasmussen T, Haaber J, Dahl IM, et al., Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica 2010; 95: 1730-1737.
63. Walker BA, Wardell CP, Johnson DC, et al., Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013; 121: 3413-3419.
64. Leung-Hagesteijn C, Erdmann N, Cheung G, et al., Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289-304.
65. Paino T, Paiva B, Sayagues JM, et al., Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia 2015; 29: 1186-1194.
66. Kapoor P, Kumar SK, Dispenzieri A, et al., Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 2013; 31: 4529-4535.
67. Kumar SK, Lee JH, Lahuerta JJ, et al., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
68. Attal M, Lauwers-Cances V, Marit G, et al., Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.
69. McCarthy PL, Owzar K, Hofmeister CC, et al., Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
70. Bendall SC, Nolan GP., From single cells to deep phenotypes in cancer. Nat Biotechnol 2012; 30: 639-647.
71. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
72. Longo DL., Tumor heterogeneity and personalized medicine. N Engl J Med 2012; 366: 956-957.
73. Zamagni E, Cavo M., The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012; 159: 499-513.
74. Mailankody S, Korde N, Lesokhin AM, et al., Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncolo 2015; 12: 286-295.
75. Stetler-Stevenson M, Paiva B, Stoolman L, et al., Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytom Part B, Clin Cytom 2015.
76. Laubach JP, Richardson PG., CD38-Targeted immunochemotherapy in refractory multiple myeloma: A new horizon. Clin Cancer Res 2015; 21: 2660-2662.
77. Hsi ED, Steinle R, Balasa B, et al., CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775-2784.